Genetic polymorphism of CYP2A6 in relation to cancer

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 428, Issue 1-2, 1999, Pages 125-130

  Kamataki, Tetsuya ^a   Nunoya, Ken Ichi ^a   Sakai, Yuki ^a   Kushida, Hirotaka ^a   Fujita, Ken Ichi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Human CYP2A6; Lung cancer; N nitrosamine; Polymorphism; Salmonella typhimurium YG7108

Indexed keywords

CYTOCHROME P450 ISOENZYME; NITROSAMINE;

CANCER; CANCER SUSCEPTIBILITY; CONFERENCE PAPER; ENZYME SPECIFICITY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN EXPERIMENT; LIVER MICROSOME METABOLISM; LUNG CANCER; METABOLIC ACTIVATION; MUTAGENICITY; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SALMONELLA TYPHIMURIUM; TOXICOKINETICS;

ARYL HYDROCARBON HYDROXYLASES; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP2E1; CYTOCHROME P-450 ENZYME SYSTEM; GENE DELETION; GENE EXPRESSION; GENE FREQUENCY; HUMANS; JAPAN; LUNG NEOPLASMS; MIXED FUNCTION OXYGENASES; MUTAGENICITY TESTS; NADPH-FERRIHEMOPROTEIN REDUCTASE; NEOPLASMS; POLYMORPHISM, GENETIC; SALMONELLA TYPHIMURIUM;

SALMONELLA TYPHIMURIUM; TYPHIMURIUM;

EID: 0032786632     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1383-5742(99)00040-X     Document Type: Conference Paper

References (8)

1. Hecht S.S. Biochemistry, biology, and carcinogenicity of tabacco-specific N-nitrosamines. Chem. Res. Toxicol. 11:1998;559-603.
2. 6-methylguanine. J. Bacteriol. 177:1995;1511-1519.
3. Fernandez-Salguero P.S., Hoffman M.G., Cholerton S., Mohrenweiser H., Raunio H., Rautio A., Pelkonen O., Huang J.-D., Evans W.E., Idle J.R., Gonzalez F.J. A genetic polymorphism in coumarin 7-hydroxylation: Sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. Am. J. Hum. Genet. 57:1995;651-660.
4. Yamano S., Tatsuno J., Gonzalez F.J. The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry. 29:1990;1322-1329.
5. Iwata H., Fujita K., Kushida H., Suzuki A., Konnno Y., Katsunori N., Fujino A., Kamataki T. High catalytic activity of human cytochrome P450 co-expressed with human NADPH-cytochrome P450 reductase in Escherichia coli. Biochem. Pharmacol. 55:1998;1315-1325.
6. Maron D.M., Ames B.N. Revised methods for the Salmonella mutagenicity test. Mutat. Res. 113:1983;173-215.
7. K. Nunoya, T. Yokoi, K. Kimura, T. Kainuma, K. Sato, M. Kinoshita, T. Kamataki, CYP2A6 gene deletion responsible for the in vivo polymorphic metabolism of (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidine-4-one hydrochloride (SM-12502) in humans, J. Pharmacol. Exptl. Therap., 1999, in press.
8. Yokoi T., Kamataki T. Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D and CYP2A6 gene in Japanese. Pharm. Res. 15:1998;517-524.